ClinicalTrials.gg
BiosimilarDrug

BP102 clinical trials

A product of Bevacizumab; its studies count on that page too.

studies test it
7
open now
3
in phase 3
3
first study started
2018

How each study uses BP102 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the BP102 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
26 Feb 2004 · AVASTIN · BLA 125085 (FDA, Drugs@FDA; as Bevacizumab)
European Union
12 Jan 2005 · Avastin · EMEA/H/C/000582 (EMA; as Bevacizumab)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

Studies by the year they started

7 studies that test it; most in 2022 (2)

Studies that test BP102, by start year
YearStudies
20181
20211
20222
20231
20252

By phase

A phase 1/2 study counts in both.

Phase 1
1
Phase 2
4
Phase 3
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 5 · Other 2

Jiangsu HengRui Medicine Co., Ltd. (2) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Fudan University (1) · Shandong Suncadia Medicine Co., Ltd. (1)

Often tested with

Tested in the same studies.

Adebrelimab (2) · Trastuzumab rezetecan (1) · Camrelizumab (1) · Famitinib (1) · Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 (1) · Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 (1) · FH-006 (1) · Anti-CTLA-4 Monoclonal Antibody SHR-8068 (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test BP102.

Studies

Open first, then newest update. How each study uses BP102 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 7

Given beside what is tested · 7 — BP102 is usual care or a partner of the new treatment